US9139529B2 - Substituted quinoxalines as sodium channel modulators - Google Patents

Substituted quinoxalines as sodium channel modulators Download PDF

Info

Publication number
US9139529B2
US9139529B2 US14/167,685 US201414167685A US9139529B2 US 9139529 B2 US9139529 B2 US 9139529B2 US 201414167685 A US201414167685 A US 201414167685A US 9139529 B2 US9139529 B2 US 9139529B2
Authority
US
United States
Prior art keywords
alkyl
another embodiment
halogen
replaced
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US14/167,685
Other languages
English (en)
Other versions
US20140228371A1 (en
Inventor
Sara Sabina Hadida-Ruah
Corey Anderson
Vijayalaksmi Arumugam
Iuliana Luci Asgian
Brian Richard Bear
Andreas P. Termin
James Philip Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US14/167,685 priority Critical patent/US9139529B2/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED reassignment VERTEX PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, ASGIAN, IULIANA LUCI, BEAR, BRIAN RICHARD, JOHNSON, JAMES PHILIP, TERMIN, ANDREAS P., ANDERSON, COREY, ARUMUGAM, VIJAYALAKSMI, HADIDA-RUAH, SARA SABINA
Assigned to MACQUARIE US TRADING LLC reassignment MACQUARIE US TRADING LLC SECURITY INTEREST Assignors: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, VERTEX PHARMACEUTICALS INCORPORATED
Publication of US20140228371A1 publication Critical patent/US20140228371A1/en
Priority to US14/813,911 priority patent/US9783501B2/en
Application granted granted Critical
Publication of US9139529B2 publication Critical patent/US9139529B2/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED, VERTEX PHARMACEUTICALS (SAN DIEGO) LLC reassignment VERTEX PHARMACEUTICALS INCORPORATED RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: MACQUARIE US TRADING LLC
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to compounds useful as inhibitors of sodium channels.
  • the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders including pain.
  • Pain is a protective mechanism that allows healthy animals to avoid tissue damage and to prevent further damage to injured tissue. Nonetheless there are many conditions where pain persists beyond its usefulness, or where patients would benefit from inhibition of pain.
  • Neuropathic pain is a form of chronic pain caused by an injury to the sensory nerves (Dieleman, J. P., et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain , 2008. 137(3): p. 681-8).
  • Neuropathic pain can be divided into two categories, pain caused by generalized metabolic damage to the nerve and pain caused by a discrete nerve injury.
  • the metabolic neuropathies include post herpetic neuropathy, diabetic neuropathy, and drug-induced neuropathy.
  • Discrete nerve injuries indications include post amputation pain, post-surgical nerve injury pain, and nerve entrapment injuries like neuropathic back pain.
  • Na V 's Voltage-gated sodium channels
  • Na V 's are key biological mediators of electrical signaling as they are the primary mediators of the rapid upstroke of the action potential of many excitable cell types (e.g. neurons, skeletal myocytes, cardiac myocytes).
  • excitable cell types e.g. neurons, skeletal myocytes, cardiac myocytes.
  • the evidence for the role of these channels in normal physiology, the pathological states arising from mutations in sodium channel genes, preclinical work in animal models, and the clinical pharmacology of known sodium channel modulating agents all point to the central role of Na V 's in pain sensation (Rush, A. M. and T. R.
  • the Na V 's form a subfamily of the voltage-gated ion channel super-family and comprises 9 isoforms, designated Nav1.1-Nav1.9.
  • the tissue localizations of the nine isoforms vary greatly.
  • Nav1.4 is the primary sodium channel of skeletal muscle
  • Nav1.5 is primary sodium channel of cardiac myocytes.
  • Na V 's 1.7, 1.8 and 1.9 are primarily localized to the peripheral nervous system, while Na V 's 1.1, 1.2, 1.3, and 1.6 are neuronal channels found in both the central and peripheral nervous systems.
  • the functional behaviors of the nine isoforms are similar but distinct in the specifics of their voltage-dependent and kinetic behavior (Catterall, W. A., Goldin, A. L., and Waxman, S. G., International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (4), p. 397 (2005)).
  • Na V 1.8 channels were identified as likely targets for analgesia (Akopian, A. N., L. Sivilotti, and J. N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature , 1996. 379(6562): p. 257-62). Since then, Na V 1.8 has been shown to be the most significant carrier of the sodium current that maintains action potential firing in small DRG neurons (Blair, N. T. and B. P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na + current, and Ca 2+ current in the action potentials of nociceptive sensory neurons. J Neurosci., 2002.
  • TTX tetrodotoxin
  • Na V 1.8 is essential for spontaneous firing in damaged neurons, like those that drive neuropathic pain (Roza, C., et al., The tetrodotoxin-resistant Na + channel Na V 1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J. Physiol., 2003. 550(Pt 3): p. 921-6; Jarvis, M. F., et al., A-803467, a potent and selective Na V 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci . USA, 2007. 104(20): p.
  • Na V 1.8 is the primary channel that mediates large amplitude action potentials in small neurons of the dorsal root ganglia (Blair, N. T. and B. P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na + current, TTX-resistant Na + current, and Ca 2+ current in the action potentials of nociceptive sensory neurons. J Neurosci., 2002. 22(23): p. 10277-90). Na V 1.8 is necessary for rapid repetitive action potentials in nociceptors, and for spontaneous activity of damaged neurons. (Choi, J. S. and S. G. Waxman, Physiological interactions between Na V 1.7 and Na V 1.8 sodium channels: a computer simulation study. J Neurophysiol.
  • Na V 1.8 is primarily restricted to the neurons that sense pain, selective Na V 1.8 blockers are unlikely to induce the adverse events common to non-selective Na V blockers. Accordingly, there remains a need to develop additional Na V channel antagonists preferably those that are more Nav1.8 selective and more potent with increased metabolic stability and with fewer side effects.
  • These compounds and pharmaceutically acceptable salts and compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.
  • the invention provides compounds of formula I:
  • compounds of the invention can optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • the variables in formula I encompass specific groups, such as, for example, alkyl and cycloalkyl.
  • combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position.
  • a ring substituent such as a heterocycloalkyl
  • substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • aliphatic means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups.
  • cycloaliphatic or “cycloalkyl” mean a monocyclic hydrocarbon ring, or a polycyclic hydrocarbon ring system that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic and has a single point of attachment to the rest of the molecule.
  • polycyclic ring system includes bicyclic and tricyclic 4- to 12-membered structures that form at least two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common) including fused, bridged, or spirocyclic ring systems.
  • halogen or “halo” as used herein, means F, Cl, Br or I.
  • heterocycle means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring atoms in one or more ring members is an independently selected heteroatom. Heterocyclic ring can be saturated or can contain one or more unsaturated bonds.
  • the “heterocycle,” “heterocyclyl,” “heterocycloaliphatic,” “heterocycloalkyl,” or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the ring system contains 3 to 7 ring members.
  • heteroatom means oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • unsaturated means that a moiety has one or more units of unsaturation but is not aromatic.
  • alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom.
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms.
  • aryl may be used interchangeably with the term “aryl ring.”
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy,” refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic.”
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Thus, included within the scope of the invention are tautomers of compounds of formula I.
  • the structures also include zwitterionic forms of the compounds or salts of formula I where appropriate. Examples of tautomeric forms include those depicted below:
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched or isotopically-labeled atoms.
  • the isotopically-labeled compounds may have one or more atoms replaced by an atom having an atomic mass or mass number usually found in nature.
  • isotopes present in compounds of formula I include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as, but not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S and 18 F.
  • Certain isotopically-labeled compounds of formula I in addition to being useful as therapeutic agents, are also useful in drug and/or substrate tissue distribution assays, as analytical tools or as probes in other biological assays.
  • tritiated (e.g., 3 H) and carbon-14 (e.g., 14 C) isotopes are useful given their ease of detectability.
  • replacement of one or more hydrogen atoms with heavier isotopes such as deuterium, (e.g., 2 H) can afford certain therapeutic advantages.
  • R group i.e. the WR W can be attached to any substitutable ring atom on either ring of the bicyclic ring system.
  • CH 2 unit or, interchangeably, methylene unit may be replaced, for example, by —O—
  • a CH 2 unit or, interchangeably, methylene unit may be replaced, for example, by —O—
  • CH 2 CH 2 CH 2 OH is within the definition of C 1 -C 6 alkyl wherein up to two non-adjacent CH 2 units may be replaced by —O— because the CH 2 unit of the terminal methyl group has been replaced by —O—.
  • the invention features a compound of formula I and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is selected from:
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is
  • a 1 is a 6 membered aromatic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur.
  • a 1 is phenyl.
  • a 1 is a 6 membered aromatic ring having 1 or 2 heteroatoms, independently selected from nitrogen.
  • a 1 is pyridyl, pyrimidinyl, pyrazinyl or triazinyl.
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is
  • a 1 is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 1 is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 1 is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is
  • a 1 is phenyl
  • a 2 is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 2 is a 5-membered aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 2 is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or triazolyl.
  • the invention features a compound of formula I and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 , In another embodiment, W is a bond and R W is halogen. In another embodiment, W is a bond and R W is OH. In another embodiment, W is a bond and R W is NH 2 , In another embodiment, W is a bond and R W is NHR′. In another embodiment, W is a bond and R W is CN. In another embodiment, W is a bond and R W is CF 3 , In another embodiment, W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I and the attendant definitions, wherein ring A is selected from:
  • the invention features a compound of formula I and the attendant definitions, wherein R 1 is H or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 2 is H, halogen, or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen and wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 2 is F, Cl, CF 3 or OCF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 3 is H, halogen or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 3 is t-butyl, Cl, CF 3 or CF 2 CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 4 is H, halogen or C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein R 1 , R 2 , R 3 and R 4 are H.
  • the invention features a compound of formula I and the attendant definitions, wherein R 5 and R 7 are each independently halogen, or —X—R X and R 5′ , R 6 , and R 6′ are each hydrogen. In another embodiment, R 5 and R 7 are each independently F, Cl, CH 3 , OCF 3 , or OCH 3 .
  • the invention features a compound of formula I and the attendant definitions, wherein ring A is selected from:
  • ring A is selected from:
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is
  • a 1 is a 6 membered aromatic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur, m is 1, W is a bond or C 1 -C 6 alkyl wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —CO—, or —SO 2 —, and R W is selected from H, OH, NH 2 , or CN.
  • a 1 is phenyl or pyridyl
  • m is 1
  • WR W is selected from H, SO 2 NH 2 , CO 2 H, SO 2 CH 3 , CONH 2 or CN.
  • the invention features a compound of formula I and the attendant definitions, wherein Ar 1 is
  • a 1 is phenyl
  • a 2 is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur
  • m is 1
  • W is a bond or C 1 -C 6 alkyl wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —CO—, or —SO 2 —
  • R W is selected from H, OH, NH 2 , or CN.
  • a 1 is phenyl
  • a 2 is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or triazolyl
  • m is 1
  • WR W is selected from H or CO 2 H.
  • the invention provides a compound of formula I-A:
  • the invention features a compound of formula I-A and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-A and the attendant definitions, wherein A 1 is a 6 membered aromatic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur. In another embodiment, A 1 is phenyl. In another embodiment, A 1 is a 6 membered aromatic ring having 1 or 2 heteroatoms, independently selected from nitrogen. In another embodiment, A 1 is pyridyl, pyrimidinyl, pyrazinyl or triazinyl.
  • the invention features a compound of formula I-A and the attendant definitions, wherein A 1 is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In another embodiment, A 1 is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In another embodiment, A 1 is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-A and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-A and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-A and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-A and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-A and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-A and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-A wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-A and the attendant definitions, wherein ring A is selected from:
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 1 , R 2 , R 3 and R 4 are H.
  • the invention features a compound of formula I-A and the attendant definitions, wherein R 5 and R 7 are each independently halogen, or —X—R X and R 5′ , R 6 , and R 6′ are each hydrogen. In another embodiment, R 5 and R 7 are each independently F, Cl, CH 3 , OCF 3 , or OCH 3 .
  • the invention provides a compound of formula I-B:
  • the invention features a compound of formula I-B and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-B and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-B and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-B and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-B and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-B and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-B wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-B and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-B and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-B-1:
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-B-1 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-B-2:
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O— —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O— —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-B-2 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-B-2 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-B-3:
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • R 6 is halogen.
  • R 6 is Cl.
  • R 6 is F.
  • R 6 is CN.
  • R 6 is —X—R X .
  • R 6 is —X—R X wherein R X is absent.
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-B-3 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-B-3 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-B-4:
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 4 is H.
  • R 4 is halogen.
  • R 4 is CN.
  • R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 4 is CF 3 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-B-4 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-B-4 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-C:
  • the invention features a compound of formula I-C and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-C and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-C and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-C and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-C and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-C and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-C wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-C and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-C and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-C-1:
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-C-1 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-C-2:
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-C-2 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-C-2 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-C-3:
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • R 6 is halogen.
  • R 6 is Cl.
  • R 6 is F.
  • R 6 is CN.
  • R 6 is —X—R X .
  • R 6 is —X—R X wherein R X is absent.
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-C-3 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-C-3 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-C-4:
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl. In another embodiment, R 7 is CF 3 . In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—. In another embodiment, R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-C-4 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-C-4 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-D:
  • the invention features a compound of formula I-D and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-D and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-D and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-D and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-D and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-D and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-D wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-D and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-D and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-D-1:
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-D-1 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-D-2:
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-D-2 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-D-2 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-D-3:
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • R 6 is halogen.
  • R 6 is Cl.
  • R 6 is F.
  • R 6 is CN.
  • R 6 is —X—R X .
  • R 6 is —X—R X wherein R X is absent.
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-D-3 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-D-3 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-D-4:
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein W is a bond and R W is a 3-6 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is a 5-membered aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • W is a bond and R W is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, triazolyl, or tetrazolyl.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein ring A 1 is selected from:
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 4 is H.
  • R 4 is halogen.
  • R 4 is CN.
  • R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 4 is CF 3 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl. In another embodiment, R 7 is CF 3 . In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—. In another embodiment, R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-D-4 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-D-4 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-E:
  • the invention features a compound of formula I-E and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-E and the attendant definitions, wherein A 1 is a 6 membered aromatic ring having 0-4 heteroatoms, independently selected from nitrogen, oxygen, or sulfur, and A 2 is a 5-membered aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 1 is phenyl and A 2 is a 5-membered aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a 1 is phenyl and A 2 is pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or triazolyl.
  • the invention features a compound of formula I-E and the attendant definitions, wherein A 1 and A 2 , together, are selected from:
  • the invention features a compound of formula I-E and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-E and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-E and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-E and the attendant definitions, A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-E wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-E and the attendant definitions, wherein ring A is selected from:
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 1 , R 2 , R 3 and R 4 are H.
  • the invention features a compound of formula I-E and the attendant definitions, wherein R 5 and R 7 are each independently halogen, or —X—R X and R 5′ , R 6 , and R 6′ are each hydrogen. In another embodiment, R 5 and R 7 are each independently F, Cl, CH 3 , OCF 3 , or OCH 3 .
  • the invention provides a compound of formula I-F:
  • the invention features a compound of formula I-F and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-F and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-F and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-F and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-F and the attendant definitions, wherein A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 5 is H. In another embodiment, R 5 is halogen. In another embodiment, R 5 is Cl. In another embodiment, R 5 is F. In another embodiment, R 5 is CN. In another embodiment, R 5 is —X—R X . In another embodiment, R 5 is —X—R X wherein R X is absent. In another embodiment, R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 5′ is H. In another embodiment, R 5′ is halogen. In another embodiment, R 5′ is Cl. In another embodiment, R 5′ is F. In another embodiment, R 5′ is CN. In another embodiment, R 5′ is —X—R X . In another embodiment, R 5′ is —X—R X wherein R X is absent. In another embodiment, R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 5′ is CH 3 .
  • R 5′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5′ is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5′ is OCH 3 .
  • R 5′ is CH 2 OH.
  • R 5′ is OCF 3 .
  • R 5′ is OCHF 2 .
  • R 6 is H. In another embodiment, R 6 is halogen. In another embodiment, R 6 is Cl. In another embodiment, R 6 is F. In another embodiment, R 6 is CN. In another embodiment, R 6 is —X—R X . In another embodiment, R 6 is —X—R X wherein R X is absent. In another embodiment, R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 6′ is H. In another embodiment, R 6′ is halogen. In another embodiment, R 6′ is Cl. In another embodiment, R 6′ is F. In another embodiment, R 6′ is CN. In another embodiment, R 6′ is —X—R X . In another embodiment, R 6′ is —X—R X wherein R X is absent. In another embodiment, R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 6′ is CH 3 .
  • R 6′ is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6′ is OCH 3 .
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-F wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-F and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-F and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-F-1:
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-F-1 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-F-2:
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-F-2 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-F-2 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-F-3:
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 4 is H. In another embodiment, R 4 is halogen. In another embodiment, R 4 is CN. In another embodiment, R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 4 is CF 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • R 6 is halogen.
  • R 6 is Cl.
  • R 6 is F.
  • R 6 is CN.
  • R 6 is —X—R X .
  • R 6 is —X—R X wherein R X is absent.
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 6 is CH 3 .
  • R 6 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 6 is OCH 3 .
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 7 is halogen.
  • R 7 is Cl.
  • R 7 is F.
  • R 7 is CN.
  • R 7 is —X—R X .
  • R 7 is —X—R X wherein R X is absent.
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl.
  • R 7 is CF 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—.
  • R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-F-3 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-F-3 and the attendant definitions, wherein ring A is selected from:
  • the invention provides a compound of formula I-F-4:
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein Y is C. In another embodiment, Y is N.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein m is zero.
  • m is an integer from 1 to 5.
  • m is 1.
  • m is 2.
  • m is 3.
  • m is 4.
  • m is 5.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein W is a bond and R W is halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is a bond and R W is halogen.
  • W is a bond and R W is OH.
  • W is a bond and R W is NH 2 .
  • W is a bond and R W is NHR′.
  • W is a bond and R W is CN.
  • W is a bond and R W is CF 3 .
  • W is a bond and R W is OCF 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , or isopropyl.
  • W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —; and R W is absent.
  • W is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or O-isopropyl.
  • W is OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • W is OCH 2 CH 2 OCH 3 , CH 2 OH, OC(CH 3 ) 3 , or CH 2 CH 2 OCH 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is H, halogen, OH, NH 2 , NHR′, NO 2 , CN, CF 3 , or OCF 3 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H, OH, NH 2 , or NHR′. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is H. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is OH.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NH 2 .
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO— and R W is NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H, OH, NH 2 , or NHR′.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is H.
  • W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is OH. In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NH 2 . In another embodiment, W is C 1 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —SO 2 — and R W is NHR′.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein W is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen, wherein up to two non-adjacent CH 2 units of said C 1 -C 6 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 2 alkyl may be replaced with —O—, —CO—, —S—, —SO—, or —SO 2 —, and R W is absent.
  • W is C 2 alkyl wherein one CH 2 unit of said C 1 alkyl is replaced with —CO—, or —SO 2 —, and R W is absent.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein A 1 and A 2 , together with WR W , are selected from:
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 1 is H. In another embodiment, R 1 is halogen. In another embodiment, R 1 is CN. In another embodiment, R 1 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 1 is CF 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 2 is H. In another embodiment, R 2 is halogen. In another embodiment, R 2 is Cl. In another embodiment, R 2 is F. In another embodiment, R 2 is CN. In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 2 is CF 3 . In another embodiment, R 2 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—. In another embodiment, R 2 is OCF 3 . In another embodiment, R 2 is F, Cl, CN, CF 3 or OCF 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 3 is H. In another embodiment, R 3 is halogen. In another embodiment, R 3 is Cl. In another embodiment, R 3 is F. In another embodiment, R 3 is CN. In another embodiment, R 3 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen. In another embodiment, R 3 is t-butyl. In another embodiment, R 3 is CF 3 . In another embodiment, R 3 is CF 2 CF 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 4 is H.
  • R 4 is halogen.
  • R 4 is CN.
  • R 4 is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 4 is CF 3 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 1 , R 2 , R 3 , and R 4 is H.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 5 is halogen.
  • R 5 is Cl.
  • R 5 is F.
  • R 5 is CN.
  • R 5 is —X—R X .
  • R 5 is —X—R X wherein R X is absent.
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 5 is CH 3 .
  • R 5 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 5 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , or OCH(CH 3 ) 2 .
  • R 5 is OCH 3 .
  • R 5 is CH 2 OH.
  • R 5 is OCF 3 .
  • R 5 is OCHF 2 .
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 7 is H. In another embodiment, R 7 is halogen. In another embodiment, R 7 is Cl. In another embodiment, R 7 is F. In another embodiment, R 7 is CN. In another embodiment, R 7 is —X—R X . In another embodiment, R 7 is —X—R X wherein R X is absent. In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen.
  • R 7 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or isopropyl. In another embodiment, R 7 is CF 3 . In another embodiment, R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein two non-adjacent CH 2 units of said C 1 -C 6 alkyl are replaced with —O—. In another embodiment, R 7 is OCH 2 CH 2 OCH 3 .
  • R 7 is —X—R X wherein R X is absent and X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O—.
  • R 7 is OCH 3 , OCH 2 CH 3 , OCH 2 CH 2 CH 3 , OC(CH 3 ) 3 , CH 2 CH 2 OCH 3 .
  • R 7 is OCF 3 , OCH 2 CF 3 , OCH 2 CH 2 CH 2 CF 3 , or OCHF 2 .
  • the invention features a compound of formula I-F-4 wherein R 7 is —X—R X wherein X is a bond and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is a bond and R X is cyclopropyl.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein R 7 is —X—R X wherein X is C 1 -C 6 alkyl wherein said C 1 -C 6 alkyl is substituted with 0-6 halogen wherein one CH 2 unit of said C 1 -C 6 alkyl is replaced with —O— and R X is C 3 -C 8 cycloaliphatic and said C 3 -C 8 cycloaliphatic is substituted with up 0-3 substituents selected from halogen and C 1 -C 4 alkyl.
  • R 7 is —X—R X wherein X is OCH 2 and R X is cyclopropyl.
  • the invention features a compound of formula I-F-4 and the attendant definitions, wherein ring A is selected from:
  • the invention features a compound of formula I or I′, wherein the compound or a pharmaceutically acceptable salt thereof, is selected from Table 1.
  • Table 1 Compounds names in Table 1 were generated using ChemBioDrawUltra version 12.0 from Cambridge Soft/Chem Office 2010.
  • the compound is 3-(4-fluoro-2-methoxyphenoxy)-N-(3-(methylsulfonyl)phenyl)quinoxaline-2-carboxamide.
  • the compound is 3-(2-chloro-4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is 3-(2-chloro-4-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is 3-(4-chloro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic acid.
  • the compound is 2-(2,4-difluorophenoxy)-N-(3-sulfamoylphenyl)quinoline-3-carboxamide.
  • the compound is 2-(4-fluoro-2-methoxyphenoxy)-N-(3-sulfamoylphenyl)quinoline-3-carboxamide.
  • the compound is 3-(2,4-difluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is N-(3-sulfamoylphenyl)-2-(4-(trifluoromethoxy)phenoxy)quinoline-3-carboxamide.
  • the compound is N-(3-sulfamoylphenyl)-3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamide.
  • the compound is 3-(4-chloro-2-methylphenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is 5-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic acid.
  • the compound is 3-(4-fluoro-2-methoxyphenoxy)-N-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)quinoxaline-2-carboxamide.
  • the compound is 3-(4-fluoro-2-methoxyphenoxy)-N-(pyridin-4-yl)quinoxaline-2-carboxamide.
  • the compound is 3-(4-fluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide.
  • the compound is N-(3-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide.
  • the compound is N-(4-carbamoylphenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide.
  • the compound is 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoic acid.
  • the compound is N-(4-cyanophenyl)-3-(4-fluoro-2-methoxyphenoxy)quinoxaline-2-carboxamide.
  • the invention provides compounds that are inhibitors of voltage-gated sodium channels, and thus the present compounds are useful for the treatment of diseases, disorders, and conditions including, but not limited to chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.
  • pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a subject in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium channel.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the pharmaceutically acceptable compositions of the invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
  • the invention features a pharmaceutical composition
  • a pharmaceutical composition comprising the compound of the invention and a pharmaceutically acceptable carrier.
  • the invention features a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof of the compounds of formula I and one or more pharmaceutically acceptable carriers or vehicles.
  • the invention features a method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject a compound of formula I or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof.
  • the voltage-gated sodium channel is Nav1.8.
  • the invention features a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia comprising administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of treating or lessening the severity in a subject of gut pain wherein gut pain comprises inflammatory bowel disease pain, Crohn's disease pain or interstitial cystitis pain.
  • the invention features a method of treating or lessening the severity in a subject of neuropathic pain
  • neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma; traumatic neuroma; Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia; post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia.
  • the invention features a method of treating or lessening the severity in a subject of musculoskeletal pain wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, burn pain or dental pain.
  • the invention features a method of treating or lessening the severity in a subject of idiopathic pain wherein idiopathic pain comprises fibromyalgia pain.
  • the invention features a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with the compound or pharmaceutical composition.
  • the invention features a method of treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn's disease pain or interstitial cystitis pain wherein said method comprises administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of treating or lessening the severity in a subject of neuropathic pain, wherein neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma, traumatic neuroma, Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia; post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia wherein said method comprises administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or
  • the invention features a method of treating or lessening the severity in a subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, burn pain or dental pain wherein said method comprises administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain or vulvodynia wherein said method comprises administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain wherein said method comprises administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method wherein the subject is treated with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the invention features a method of inhibiting a voltage-gated sodium channel in a subject comprising administering to the subject an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the voltage-gated sodium channel is Nav1.8.
  • the invention features a method of inhibiting a voltage-gated sodium channel in a biological sample comprising contacting the biological sample with an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the voltage-gated sodium channel is Nav1.8.
  • the invention features a method of treating or lessening the severity in a subject of acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head pain, neck pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress induced angina, exercise induced angina, palpitations, hypertension, or abnormal gastro-intestinal
  • the invention features a method of treating or lessening the severity in a subject of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache pain; migraine; tension headache, cluster headaches; chronic and acute neuropathic pain, post-herpetic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain;
  • the invention features a method of treating or lessening the severity in a subject of neuropathic pain comprising administering an effective amount of a compound, a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the compounds of formula I.
  • the neuropathic pain is selected from post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma, traumatic neuroma, Morton's neuroma, nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain, nerve avulsion injury, brachial plexus avulsion, complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia, post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in inhibiting a voltage-gated sodium channel.
  • the voltage-gated sodium channel is Nav1.8.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of gut pain, wherein gut pain comprises inflammatory bowel disease pain, Crohn's disease pain or interstitial cystitis pain.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in a treating or lessening the severity in a subject of neuropathic pain
  • neuropathic pain comprises post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma, traumatic neuroma, Morton's neuroma; nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain; nerve avulsion injury, brachial plexus avulsion injury; complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia; post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of musculoskeletal pain, wherein musculoskeletal pain comprises osteoarthritis pain, back pain, cold pain, burn pain or dental pain.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of inflammatory pain, wherein inflammatory pain comprises rheumatoid arthritis pain or vulvodynia.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity in a subject of idiopathic pain, wherein idiopathic pain comprises fibromyalgia pain.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament in combination with one or more additional therapeutic agents administered concurrently with, prior to, or subsequent to treatment with the compound or pharmaceutical composition.
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity of acute pain, chronic pain, neuropathic pain, inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy, epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head pain, neck pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress induced angina, exercise induced angina
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic pain; IBS pain; chronic and acute headache pain; migraine; tension headache, including, cluster headaches; chronic and acute neuropathic pain, post-herpetic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain;
  • the invention provides the use of a compound or pharmaceutical composition described herein for the manufacture of a medicament for use in treating or lessening the severity of neuropathic pain.
  • the neuropathic pain is selected from post-herpetic neuralgia, diabetic neuralgia, painful HIV-associated sensory neuropathy, trigeminal neuralgia, burning mouth syndrome, post-amputation pain, phantom pain, painful neuroma, traumatic neuroma, Morton's neuroma, nerve entrapment injury, spinal stenosis, carpal tunnel syndrome, radicular pain, sciatica pain, nerve avulsion injury, brachial plexus avulsion, complex regional pain syndrome, drug therapy induced neuralgia, cancer chemotherapy induced neuralgia, anti-retroviral therapy induced neuralgia, post spinal cord injury pain, idiopathic small-fiber neuropathy, idiopathic sensory neuropathy or trigeminal autonomic cephalalgia.
  • an “effective amount” of the compound, a pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence or cardiac arrhythmia.
  • the compounds and compositions, according to the method of the invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of the pain or non-pain diseases recited herein.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as, for example, water or other solvents, solubil
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar—agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as inhibitors of voltage-gated sodium channels.
  • the compounds and compositions of the invention are inhibitors of Na V 1.8 and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of Na V 1.8 is implicated in the disease, condition, or disorder.
  • the disease, condition, or disorder may also be referred to as a “Na V 1.8-mediated disease, condition or disorder.” Accordingly, in another aspect, the invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of Na V 1.8 is implicated in the disease state.
  • the activity of a compound utilized in this invention as an inhibitor of Na V 1.8 may be assayed according to methods described generally in the Examples herein, or according to methods available to one of ordinary skill in the art.
  • the compounds and pharmaceutically acceptable compositions of the invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated.”
  • exemplary additional therapeutic agents include, but are not limited to: nonopioid analgesics (indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin; naphthylalkanones such sa Nabumetone; oxicams such as Piroxicam; para-aminophenol derivatives, such as Acetaminophen; propionic acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Aspirin, Choline magnesium trisalicylate, Diflunisal; fenamates such as meclofenamic acid, Mefenamic acid; and pyrazoles such as Phenylbutazone); or opioid (narc
  • nondrug analgesic approaches may be utilized in conjunction with administration of one or more compounds of the invention.
  • anesthesiologic intraspinal infusion, neural blockade
  • neurosurgical neurolysis of CNS pathways
  • neurostimulatory transcutaneous electrical nerve stimulation, dorsal column stimulation
  • physiatric physical therapy, orthotic devices, diathermy
  • psychologic psychologic
  • additional appropriate therapeutic agents are selected from the following:
  • an opioid analgesic e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine or pentazocine;
  • opioid analgesic e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nal
  • NSAID nonsteroidal antiinflammatory drug
  • NSAID nonsteroidal antiinflammatory drug
  • diclofenac diflunisal, etodolac
  • fenbufen fenoprofen
  • flufenisal flurbiprofen
  • ibuprofen indomethacin
  • ketoprofen ketorolac
  • meclofenamic acid mefenamic acid, meloxicam
  • nabumetone naproxen
  • nimesulide nitroflurbiprofen
  • olsalazine oxaprozin
  • phenylbutazone piroxicam
  • sulfasalazine sulindac
  • tolmetin or zomepirac a nonsteroidal antiinflammatory drug
  • a barbiturate sedative e.g. amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, methohexital, pentobarbital, phenobarbital, secobarbital, talbutal, thiamylal or thiopental;
  • a benzodiazepine having a sedative action e.g. chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam or triazolam;
  • H 1 histamine (H 1 ) antagonist having a sedative action, e.g. diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorcyclizine;
  • a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;
  • a skeletal muscle relaxant e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol or orphenadrine;
  • an NMDA receptor antagonist e.g. dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex®), a combination formulation of morphine and dextromethorphan), topiramate, neramexane or perzinfotel including an NR2B antagonist, e.g.
  • an alpha-adrenergic e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmedetomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,2,3,4-tetrahydroisoquinolin-2-yl)-5-(2-pyridyl) quinazoline;
  • a tricyclic antidepressant e.g. desipramine, imipramine, amitriptyline or nortriptyline;
  • an anticonvulsant e.g. carbamazepine (Tegretol®), lamotrigine, topiramate, lacosamide (Vimpat®) or valproate;
  • a tachykinin (NK) antagonist particularly an NK-3, NK-2 or NK-1 antagonist, e.g. (alphaR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6-13-dione (TAK-637), 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamin
  • a muscarinic antagonist e.g oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;
  • a COX-2 selective inhibitor e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;
  • a neuroleptic such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindore, eplivanserin, osanetant, rimonabant, meclinertant, Miraxion® or sarizotan;
  • a vanilloid receptor agonist e.g. resinferatoxin or civamide
  • antagonist e.g. capsazepine, GRC-15300
  • a beta-adrenergic such as propranolol
  • a corticosteroid such as dexamethasone
  • a 5-HT receptor agonist or antagonist particularly a 5-HT 1B/1D agonist such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan;
  • a 5-HT 2A receptor antagonist such as R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);
  • a cholinergic (nicotinic) analgesic such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) or nicotine;
  • a PDE5 inhibitor such as 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2′,1′:6,1]-pyrido[3,4-b]indole-1,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-
  • an alpha-2-delta ligand such as gabapentin (Neurontin®), gabapentin GR (Gralise®), gabapentin, enacarbil (Horizant®), pregabalin (Lyrica®), 3-methyl gabapentin, (1[alpha],3[alpha],5[alpha])(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]
  • a serotonin reuptake inhibitor such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine desmethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,1-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine and trazodone;
  • a noradrenaline (norepinephrine) reuptake inhibitor such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, bupropion, bupropion metabolite hydroxybupropion, nomifensine and viloxazine (Vivalan®), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine;
  • a dual serotonin-noradrenaline reuptake inhibitor such as venlafaxine, venlafaxine metabolite 0-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine (Cymbalta®), milnacipran and imipramine;
  • an inducible nitric oxide synthase (iNOS) inhibitor such as S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine, 5-[2-[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyridinecarbonitrile; 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)
  • a prostaglandin E2 subtype 4 (EP4) antagonist such as N-[( ⁇ 2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl ⁇ amino)-carbonyl]-4-methylbenzene sulfonamide or 4-[(15)-1-( ⁇ [5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl ⁇ amino)ethyl]benzoic acid;
  • a leukotriene B4 antagonist such as 1-(3-biphenyl-4-ylmethyl-4-hydroxy-chroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-Carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]-valeric acid (ONO-4057) or DPC-11870;
  • a 5-lipoxygenase inhibitor such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone (ZD-2138), or 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone (CV-6504);
  • a sodium channel blocker such as lidocaine, lidocaine plus tetracaine cream (ZRS-201) or eslicarbazepine acetate;
  • an Na V 1.7 blocker such as XEN-402 and such as those disclosed in WO2011/140425; WO2012/106499; WO2012/112743; WO2012/125613 or PCT/US2013/21535 the entire contents of each application hereby incorporated by reference.
  • an Na V 1.8 blocker such as those disclosed in WO2008/135826 and WO2006/011050 the entire contents of each application hereby incorporated by reference.
  • a combined Na V 1.7 and Na V 1.8 blocker such as DSP-2230 or BL-1021;
  • a 5-HT3 antagonist such as ondansetron
  • TPRV 1 receptor agonist such as capsaicin (NeurogesX®, Qutenza®); and the pharmaceutically acceptable salts and solvates thereof;
  • a nicotinic receptor antagonist such as varenicline
  • N-type calcium channel antagonist such as Z-160
  • a nerve growth factor antagonist such as tanezumab
  • an angiotensin II antagonist such as EMA-401
  • the additional appropriate therapeutic agents are selected from V-116517, Pregabalin, controlled release Pregabalin, Ezogabine (Potiga®). Ketamine/amitriptyline topical cream (Amiket®), AVP-923, Perampanel (E-2007), Ralfinamide, transdermal bupivacaine (Eladur®), CNV1014802, JNJ-10234094 (Carisbamate), BMS-954561 or ARC-4558.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 10% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the invention in another aspect, includes a composition for coating an implantable device comprising a compound of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the invention includes an implantable device coated with a composition comprising a compound of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to inhibiting Na V 1.8 activity in a biological sample or a subject, which method comprises administering to the subject, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of Na V 1.8 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium channels in biological and pathological phenomena; and the comparative evaluation of new sodium channel inhibitors.
  • the compounds of the invention may be prepared readily using the following methods. Illustrated below in Scheme 1 is a general method for preparing the compounds of the present invention.
  • reaction was cooled to 25° C., filtered and purified by reverse phase preparative chromatography utilizing a gradient of 10-99% acetonitrile in water containing HCl as a modifier to yield 5-(3-(2,4-dimethoxyphenoxy)quinoxaline-2-carboxamido)picolinic acid (26) (26.63 mg, 36%).
  • 5-(2-(2,4-Difluorophenoxy)quinoline-3-carboxamido)picolinic acid (34) was prepared as described above from 2,4-difluorophenol.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
US14/167,685 2013-01-31 2014-01-29 Substituted quinoxalines as sodium channel modulators Active US9139529B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/167,685 US9139529B2 (en) 2013-01-31 2014-01-29 Substituted quinoxalines as sodium channel modulators
US14/813,911 US9783501B2 (en) 2013-01-31 2015-07-30 Substituted quinolines as modulators of sodium channels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759300P 2013-01-31 2013-01-31
US14/167,685 US9139529B2 (en) 2013-01-31 2014-01-29 Substituted quinoxalines as sodium channel modulators

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/813,911 Division US9783501B2 (en) 2013-01-31 2015-07-30 Substituted quinolines as modulators of sodium channels
US14/813,911 Continuation US9783501B2 (en) 2013-01-31 2015-07-30 Substituted quinolines as modulators of sodium channels

Publications (2)

Publication Number Publication Date
US20140228371A1 US20140228371A1 (en) 2014-08-14
US9139529B2 true US9139529B2 (en) 2015-09-22

Family

ID=50073532

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/167,685 Active US9139529B2 (en) 2013-01-31 2014-01-29 Substituted quinoxalines as sodium channel modulators
US14/813,911 Active US9783501B2 (en) 2013-01-31 2015-07-30 Substituted quinolines as modulators of sodium channels

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/813,911 Active US9783501B2 (en) 2013-01-31 2015-07-30 Substituted quinolines as modulators of sodium channels

Country Status (20)

Country Link
US (2) US9139529B2 (fr)
EP (1) EP2951168B1 (fr)
JP (1) JP6362623B2 (fr)
KR (1) KR102226587B1 (fr)
CN (1) CN105073738B (fr)
AR (1) AR095192A1 (fr)
AU (1) AU2014212426B8 (fr)
BR (1) BR112015017997B1 (fr)
CA (1) CA2898650C (fr)
ES (1) ES2620379T3 (fr)
HK (1) HK1217691A1 (fr)
HU (1) HUE032169T2 (fr)
IL (1) IL240091B (fr)
MX (1) MX368833B (fr)
NZ (1) NZ710111A (fr)
RU (1) RU2683788C2 (fr)
SG (1) SG11201505952WA (fr)
TW (1) TWI631105B (fr)
WO (1) WO2014120815A1 (fr)
ZA (1) ZA201505326B (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464102B2 (en) 2013-12-13 2016-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9758483B2 (en) 2013-01-31 2017-09-12 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US9783501B2 (en) 2013-01-31 2017-10-10 Vertex Pharmaceuticals Incorporated Substituted quinolines as modulators of sodium channels
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11203571B2 (en) 2013-07-19 2021-12-21 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606367YA (en) * 2014-02-06 2016-09-29 Abbvie Inc 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof
SG11202100137TA (en) 2018-07-09 2021-02-25 Lieber Institute Inc PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
CA3105657A1 (fr) * 2018-07-09 2020-01-16 Lieber Institute, Inc. Composes de pyridine carboxamide pour inhiber nav1.8
CN108997230B (zh) * 2018-07-26 2020-08-04 山东大学 具有基质金属蛋白酶抑制活性的喹喔啉衍生物及其制备方法和应用
WO2020092667A1 (fr) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
WO2020132014A1 (fr) 2018-12-19 2020-06-25 Celgene Corporation Composés de 3-((3-aminophényl)amino)pipéridine-2,6-dione substitués, compositions de ceux-ci et procédés de traitement associés
BR112021012186A2 (pt) 2018-12-19 2021-08-31 Celgene Corporation Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
WO2020146682A1 (fr) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides utilisés en tant que modulateurs de canaux sodiques
US20220110923A1 (en) 2019-01-10 2022-04-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (fr) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Forme posologique comprenant un promédicament inhibiteur de canal sodique na 1,8
WO2020219867A1 (fr) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Compositions de co-cristaux d'amide de pyridone pour le traitement de la douleur
AU2020302338A1 (en) * 2019-06-27 2022-01-27 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as NAV1.8 inhibitors
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
PE20221515A1 (es) * 2019-09-12 2022-10-04 Shanghai Jemincare Pharmaceuticals Co Ltd Oxinitruro de piridina, metodo para su preparacion y uso de este
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
EP4168393A1 (fr) 2020-06-17 2023-04-26 Merck Sharp & Dohme LLC 2-oxoimidazolidine-4-carboxamides utilisés en tant qu'inhibiteurs de nav1.8
CN112225695B (zh) * 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
WO2022129281A1 (fr) * 2020-12-18 2022-06-23 Glaxosmithkline Intellectual Property Development Limited Composés 2,3-dihydroquinazoline contenant de l'azote servant d'inhibiteurs de nav1.8
WO2022235859A1 (fr) 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopipérazine carboxamides et cyclohétéroalkyle 3-oxopipérazine carboxamides en tant qu'inhibiteurs de nav1.8
CN117794918A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 经取代的四氢呋喃类似物作为钠通道调节剂
EP4347584A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Analogues de n-(hydroxyalkyl(hétéro)aryl)tétrahydrofurane carboxamide en tant que modulateurs de canaux sodiques
JP2024520649A (ja) 2021-06-04 2024-05-24 バーテックス ファーマシューティカルズ インコーポレイテッド （２ｒ，３ｓ，４ｓ，５ｒ）－４－［［３－（３，４－ジフルオロ－２－メトキシ－フェニル）－４，５－ジメチル－５－（トリフルオロメチル）テトラヒドロフラン－２－カルボニル］アミノ］ピリジン－２－カルボキサミドを含む固体剤形及び投与レジメン
EP4347033A1 (fr) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Tétrahydrofuranes à substitution hydroxy et (halo)alkoxy utiles en tant que modulateurs de canaux sodiques
WO2022256702A1 (fr) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Tétrahydrofuran-2-carboxamides substitués utiles en tant que modulateurs de canaux sodiques
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2023138599A1 (fr) * 2022-01-18 2023-07-27 成都康弘药业集团股份有限公司 Inhibiteur de nav1.8 à cycle condensé aromatique et son utilisation
US20230382910A1 (en) 2022-04-22 2023-11-30 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryles pour le traitement de la douleur
WO2023205468A1 (fr) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Composés hétéroaryle pour le traitement de la douleur
US20230373925A1 (en) 2022-04-22 2023-11-23 Vertex Pharma Heteroaryl compounds for the treatment of pain
WO2023211990A1 (fr) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2705446A1 (de) 1976-02-11 1977-08-18 Roussel Uclaf Neue derivate der 3-chinolincarbonsaeure, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
FR2377400A2 (fr) 1977-01-18 1978-08-11 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
DE3320102A1 (de) 1982-06-03 1983-12-08 Roussel-Uclaf, 75007 Paris Neue, in 2-stellung substituierte derivate der 4-hydroxy-3-chinolincarbonsaeure, deren herstellung, deren verwendung als arzneimittel, die sie enthaltenden zusammensetzungen und erhaltene zwischenprodukte
US20070238733A1 (en) 2006-04-11 2007-10-11 Pramod Joshi Compositions useful as inhibitors of voltage-gated sodium channels
US20090099233A1 (en) 2007-10-11 2009-04-16 Pramod Joshi Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US20090118333A1 (en) 2007-10-11 2009-05-07 Weichuan Caroline Chen Amides useful as inhibitors of voltage-gated sodium channels
US20090118338A1 (en) 2007-10-11 2009-05-07 Weichuan Caroline Chen Aryl amides useful as inhibitors of voltage-gated sodium channels
WO2010053757A1 (fr) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. Inhibiteurs, à base de 2-oxoquinoxaline, des canaux sodiques tardifs
WO2010056865A1 (fr) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Dérivés de quinoléine au titre de modulateurs de canaux ioniques
WO2014120815A1 (fr) * 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Quinoléine et quinazoline amides comme modulateurs des canaux sodiques

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3210063A1 (de) 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
CN1018837B (zh) 1991-03-12 1992-10-28 淄博齐新塑料厂 改性聚丙烯洗衣机内桶料及制备
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
NZ337698A (en) * 1997-04-04 2001-07-27 Pfizer Prod Inc Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases
CN1128790C (zh) * 1997-12-22 2003-11-26 法玛西雅厄普约翰美国公司 用作抗病毒剂的4－羟基喹啉－3－甲酰胺和酰肼化合物
TW200524888A (en) * 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
CA2574600C (fr) 2004-07-23 2010-08-31 Pfizer Inc. Derives de pyridine
JP5527761B2 (ja) * 2007-03-23 2014-06-25 アムジエン・インコーポレーテツド 複素環化合物およびそれの使用
SA08290245B1 (ar) * 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
EA015952B1 (ru) 2007-05-03 2011-12-30 Пфайзер Лимитед 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
CA2801032A1 (fr) * 2010-07-12 2012-01-19 Pfizer Limited Derives de n-sulfonylbenzamide utiles comme inhibiteurs du canal sodique voltage-dependant
EP2670752B1 (fr) 2011-02-02 2016-03-16 Vertex Pharmaceuticals Incorporated Amides de pipéridine spirocyclique-pyrrolopyrazine en tant que modulateurs de canaux ioniques
EP2675812B1 (fr) 2011-02-18 2017-08-30 Vertex Pharmaceuticals Incorporated Amides de pipéridine spirocyclique chromanique en tant que modulateurs des canaux ioniques
CN103517910B (zh) 2011-03-14 2016-12-14 沃泰克斯药物股份有限公司 作为离子通道调节剂的吗啉-螺环哌啶酰胺
WO2014120820A1 (fr) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides comme modulateurs des canaux sodiques
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
UA119147C2 (uk) 2013-07-19 2019-05-10 Вертекс Фармасьютікалз Інкорпорейтед Сульфонаміди як модулятори натрієвих каналів
DK3080134T3 (en) 2013-12-13 2018-10-22 Vertex Pharma PRODRUGS OF PYRIDONAMIDS USED AS MODULATORS OF SODIUM CHANNELS

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2705446A1 (de) 1976-02-11 1977-08-18 Roussel Uclaf Neue derivate der 3-chinolincarbonsaeure, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
US4107310A (en) 1976-02-11 1978-08-15 Roussel Uclaf Quinoline-3-carboxamides
FR2377400A2 (fr) 1977-01-18 1978-08-11 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
DE3320102A1 (de) 1982-06-03 1983-12-08 Roussel-Uclaf, 75007 Paris Neue, in 2-stellung substituierte derivate der 4-hydroxy-3-chinolincarbonsaeure, deren herstellung, deren verwendung als arzneimittel, die sie enthaltenden zusammensetzungen und erhaltene zwischenprodukte
US4486438A (en) 1982-06-03 1984-12-04 Roussel Uclaf 4-Hydroxy-3-quinoline-carboxylic acid derivatives
US20070238733A1 (en) 2006-04-11 2007-10-11 Pramod Joshi Compositions useful as inhibitors of voltage-gated sodium channels
US20090099233A1 (en) 2007-10-11 2009-04-16 Pramod Joshi Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US20090118333A1 (en) 2007-10-11 2009-05-07 Weichuan Caroline Chen Amides useful as inhibitors of voltage-gated sodium channels
US20090118338A1 (en) 2007-10-11 2009-05-07 Weichuan Caroline Chen Aryl amides useful as inhibitors of voltage-gated sodium channels
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
US8519137B2 (en) 2007-10-11 2013-08-27 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US20130231370A1 (en) 2007-10-11 2013-09-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2010053757A1 (fr) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. Inhibiteurs, à base de 2-oxoquinoxaline, des canaux sodiques tardifs
WO2010056865A1 (fr) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Dérivés de quinoléine au titre de modulateurs de canaux ioniques
WO2014120815A1 (fr) * 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Quinoléine et quinazoline amides comme modulateurs des canaux sodiques

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
Akopian, A.N., L. Sivilotti, and J.N. Wood, A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature, 1996. 379(6562): p. 257-62).
Black, J.A., et al., Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol, 2008. 64(6): p. 644-53.
Blair, N. T. and B.P. Bean, Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci., 2002. 22(23): p. 10277-90).
Catterall, W. A., Goldin, A. L., and Waxman, S. G., International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (4), p. 397 (2005).
Chahine, M., Chatelier, A., Babich, O., and Krupp, J. J., Voltage-gated sodium channels in neurological disorders. CNS Neurol Disord Drug Targets 7 (2), p. 144-58 (2008).
Choi, J.S. and S.G. Waxman, Physiological interactions between NaV1.7 and NaV1.8 sodium channels: a computer simulation study. J Neurophysiol. 106(6): p. 3173-84.
Coward, K., et al., Immunolocalization of SNS/PN3 and NaN/SNS2 sodium channels in human pain states. Pain, 2000. 85(1-2): p. 41-50.
Dieleman, J.P., et al., Incidence rates and treatment of neuropathic pain conditions in the general population. Pain, 2008. 137(3): p. 681-8.
Dong, X.W., et al., Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats. Neuroscience, 2007. 146(2): p. 812-21.
England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin Investig Drugs 17 (12), p. 1849-64 (2008).
Hackam, et al. JAMA, 296(14), 2006, 1731-1732. *
Huang, H.L., et al., Proteomic profiling of neuromas reveals alterations in protein composition and local protein synthesis in hyper-excitable nerves. Mol Pain, 2008. 4: p. 33.
International Search Report and Written Opinion of the International Searching Authority, International Patent Application No. PCT/US2014/013662 (Apr. 1, 2014).
Jarvis, M.F., et al., A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci. U S A, 2007. 104(20): p. 8520-8525.
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205. *
Joshi, S.K., et al., Involvement of the TTX-resistant sodium channel Nav1.8 in inflammatory and neuropathic, but not post-operative, pain states. Pain, 2006. 123(1-2): pp. 75-82.
Krafte, D. S. and Bannon, A. W., Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr Opin Pharmacol 8 (1), p. 50-56 (2008).
Lai, J., et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain, 2002. 95(1-2): p. 143-152.
Qiu, F., et al., Increased expression of tetrodotoxin-resistant sodium channels NaV1.8 and NaV1.9 within dorsal root ganglia in a rat model of bone cancer pain. Neurosci. Lett. 512(2): p. 61-66.
Renganathan, M., T.R. Cummins, and S.G. Waxman, Contribution of Na(V)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol., 2001. 86(2): p. 629-640.
Roza, C., et al., The tetrodotoxin-resistant Na+ channel NaV1.8 is essential for the expression of spontaneous activity in damaged sensory axons of mice. J Physiol., 2003. 550(Pt 3): p. 921-926.
Ruangsri, S., et al., Relationship of axonal voltage-gated sodium channel 1.8 (NaV1.8) mRNA accumulation to sciatic nerve injury-induced painful neuropathy in rats. J Biol Chem. 286(46): p. 39836-39847.
Rush, A.M. and T.R. Cummins, Painful Research: Identification of a Small-Molecule Inhibitor that Selectively Targets NaV1.8 Sodium Channels. Mol Interv, 2007 7(4): p. 192-195.
Rush, A.M., et al., A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Aced Sci USA, 2006. 103(21): p. 8245-8250.
Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action. Eur J Pain 6 Suppl A, p. 3-9 (2002).
Strickland, I.T., et al., Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain, 2008. 12(5): p. 564-72.
Sun, W., et al., Reduced conduction failure of the main axon of polymodal nociceptive C-fibres contributes to painful diabetic neuropathy in rats. Brain. 135(Pt 2): p. 359-75.
Wang, G. K., Mitchell, J., and Wang, S. Y., Block of persistent late Na+ currents by antidepressant sertraline and paroxetine. J Membr Biol 222 (2), p. 79-90 (2008).
Yiangou, Y., et al., SNS/PN3 and SNS2/NaN sodium channel-like immunoreactivity in human adult and neonate injured sensory nerves. FEBS Lett, 2000. 467(2-3): p. 249-252.

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738009B2 (en) 2013-01-31 2020-08-11 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US9758483B2 (en) 2013-01-31 2017-09-12 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US9783501B2 (en) 2013-01-31 2017-10-10 Vertex Pharmaceuticals Incorporated Substituted quinolines as modulators of sodium channels
US11673864B2 (en) 2013-01-31 2023-06-13 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US10087143B2 (en) 2013-01-31 2018-10-02 Vertex Pharmaceuticals Incorporated Pyridone amides as modulators of sodium channels
US11203571B2 (en) 2013-07-19 2021-12-21 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
US10787472B2 (en) 2013-12-13 2020-09-29 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9464102B2 (en) 2013-12-13 2016-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US10253054B2 (en) 2013-12-13 2019-04-09 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US9828397B2 (en) 2013-12-13 2017-11-28 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11773119B2 (en) 2013-12-13 2023-10-03 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US10647661B2 (en) 2017-07-11 2020-05-12 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11603351B2 (en) 2017-07-11 2023-03-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US11529337B2 (en) 2018-02-12 2022-12-20 Vertex Pharmaceuticals Incorporated Method of treating pain
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
MX2015009592A (es) 2015-11-25
HUE032169T2 (en) 2017-09-28
TWI631105B (zh) 2018-08-01
BR112015017997A2 (pt) 2017-07-11
HK1217691A1 (zh) 2017-01-20
JP6362623B2 (ja) 2018-07-25
ES2620379T3 (es) 2017-06-28
IL240091A0 (en) 2015-09-24
AR095192A1 (es) 2015-09-30
US20140228371A1 (en) 2014-08-14
CA2898650A1 (fr) 2014-08-07
CN105073738B (zh) 2018-01-05
BR112015017997B1 (pt) 2023-03-07
RU2015136770A (ru) 2017-03-07
EP2951168A1 (fr) 2015-12-09
MX368833B (es) 2019-10-18
SG11201505952WA (en) 2015-08-28
WO2014120815A1 (fr) 2014-08-07
BR112015017997A8 (pt) 2019-11-05
IL240091B (en) 2019-03-31
US20150336945A1 (en) 2015-11-26
ZA201505326B (en) 2017-11-29
CN105073738A (zh) 2015-11-18
KR102226587B1 (ko) 2021-03-11
US9783501B2 (en) 2017-10-10
RU2683788C2 (ru) 2019-04-02
AU2014212426B8 (en) 2018-05-10
EP2951168B1 (fr) 2017-01-04
TW201443022A (zh) 2014-11-16
AU2014212426B2 (en) 2018-04-26
WO2014120815A9 (fr) 2015-06-25
JP2016506964A (ja) 2016-03-07
KR20150114536A (ko) 2015-10-12
AU2014212426A1 (en) 2015-08-06
NZ710111A (en) 2020-08-28
CA2898650C (fr) 2021-09-07

Similar Documents

Publication Publication Date Title
US9783501B2 (en) Substituted quinolines as modulators of sodium channels
US11673864B2 (en) Pyridone amides as modulators of sodium channels
US11773119B2 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
US9421196B2 (en) Amides as modulators of sodium channels
US11203571B2 (en) Sulfonamides as modulators of sodium channels

Legal Events

Date Code Title Description
AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HADIDA-RUAH, SARA SABINA;ANDERSON, COREY;ARUMUGAM, VIJAYALAKSMI;AND OTHERS;SIGNING DATES FROM 20140307 TO 20140312;REEL/FRAME:032415/0136

AS Assignment

Owner name: MACQUARIE US TRADING LLC, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNORS:VERTEX PHARMACEUTICALS INCORPORATED;VERTEX PHARMACEUTICALS (SAN DIEGO) LLC;REEL/FRAME:033292/0311

Effective date: 20140709

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001

Effective date: 20161013

Owner name: VERTEX PHARMACEUTICALS (SAN DIEGO) LLC, CALIFORNIA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MACQUARIE US TRADING LLC;REEL/FRAME:040357/0001

Effective date: 20161013

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8